Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Am J Cardiol. 2023 Apr 1;196:89–98. doi: 10.1016/j.amjcard.2023.03.002

Figure 6. Monthly fill rates for GLP-1 RA and SGLT-2i prescriptions among new initiators across patient subgroups in 2019–2020.

Figure 6.

Data represent monthly fill rates based on the proportion of days covered among new initiators of each drug class for 12 months after initiating treatment. Abbreviations: ASCVD, atherosclerotic cardiovascular disease; GLP-1; glucagon-like peptide-1 receptor agonist; SGLT-2, sodium glucose cotransporter-2 inhibitor.